Detalhe da pesquisa
1.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Cancer Immunol Immunother
; 70(6): 1583-1592, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231726
2.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Mediators Inflamm
; 2019: 7652014, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827379
3.
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.
Crit Rev Oncol Hematol
; 184: 103929, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36773668
4.
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Expert Rev Anticancer Ther
; 22(8): 785-794, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35726802
5.
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
Anticancer Res
; 42(3): 1487-1493, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220243
6.
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.
Semin Oncol
; 49(5): 389-393, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36184311
7.
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
Front Oncol
; 12: 1026020, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36387232
8.
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
J Hematol Oncol
; 15(1): 9, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35062993
9.
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned.
Cells
; 10(10)2021 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34685665
10.
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Transl Lung Cancer Res
; 10(7): 3369-3384, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430373
11.
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.
Front Oncol
; 11: 792385, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35004317
12.
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.
Front Oncol
; 11: 650293, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33937057
13.
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Clin Lung Cancer
; 22(4): 351-360, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33558194
14.
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Cancers (Basel)
; 12(5)2020 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32397295
15.
Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?
Transl Cancer Res
; 9(2): 409-414, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35117384
16.
Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine.
Transl Lung Cancer Res
; 7(Suppl 4): S312-S317, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30705843